Intensive blood-pressure control in hypertensive chronic kidney disease

New England Journal of Medicine

Volumn 363, Issue 10, 2010, Pages 918-929

  Appel, Lawrence J ^a   Wright Jr , Jackson T ^c   Greene, Tom ^e   Agodoa, Lawrence Y ^f   Astor, Brad C ^a   Bakris, George L ^g   Cleveland, William H ⁱ   Charleston, Jeanne ^b   Contreras, Gabriel ^k   Faulkner, Marquetta L ^l   Gabbai, Francis B ⁿ   Gassman, Jennifer J ^d   Hebert, Lee A ^o   Jamerson, Kenneth A ^p   Kopple, Joel D ^q   Kusek, John W ^f   Lash, James P ^h   Lea, Janice P ^j   Lewis, Julia B ^m   Lipkowitz, Michael S ^u   Massry, Shaul G ^r   Miller, Edgar R ^a   Norris, Keith ^s   Phillips, Robert A ^w   Pogue, Velvie A ^v   Randall, Otelio S ^x   Rostand, Stephen G ^y   Smogorzewski, Miroslaw J ^t   Toto, Robert D ^z   Wang, Xuelei ^d   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ MOREHOUSE SCHOOL OF MEDICINE   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^l MEHARRY MEDICAL COLLEGE   (United States)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^o THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^p UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^q UCLA MEDICAL CENTER   (United States)

^r LAC USC MEDICAL CENTER   (United States)

^s CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^t UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^u MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^v Och Spine at New York Presbyterian Hospitals   (United States)

^w UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^x HOWARD UNIVERSITY HOSPITAL   (United States)

^y University of Alabama at Birmingham   (United States)

^z UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CLONIDINE; CREATININE; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MINOXIDIL; RAMIPRIL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEINURIA;

EID: 77956274457     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0910975     Document Type: Article

References (29)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
2. U.S. Renal Data System. Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. Endstage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 1997;277:1293-8. (Pubitemid 27194353)
4. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
5. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31. [Erratum, JAMA 2006;295:2726.]
6. Jafar TH, Stark P, Schmid C, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52.
7. The ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361:1639-50.
8. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009;3:CD004349.
9. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
10. Kidney Diseases Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004,43:Suppl 1:S1-S290.
11. Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232.
12. Padwal RS, Hemmelgarn BR, Khan NA, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009;25:279-86.
13. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85. (Pubitemid 15087125)
14. Gassman JJ, Greene T, Wright JT Jr, et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2003;14:Suppl 2:S154-S165.
15. Appel LJ, Middleton J, Miller ER III, et al. The rationale and design of the AASK Cohort Study. J Am Soc Nephrol 2003;14:Suppl 2:S166-S172.
16. Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008;168:832-9.
17. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-28.
18. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Berlin: Springer-Verlag, 1997.
19. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
20. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 2005;142:342-51.
21. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87. [Erratum, Ann Intern Med 2002;137:299.]
22. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
23. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006;21:1257-62.
24. Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:830-7.
25. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-37.
26. Coresh J, Longenecker JC, Miller ER III, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9:Suppl:S24-S30.
27. Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009;53:20-7.
28. Norris KC, Greene T, Kopple J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006;17:2928-36.
29. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.